Guobang Pharma (SH:605507)2021-10-18 16:00Financial Performance - Q3 2021 revenue was CNY 970,805,310.32, a decrease of 4.34% compared to the same period last year[5] - Net profit attributable to shareholders was CNY 143,392,791.45, down 24.78% year-over-year[5] - Basic earnings per share decreased by 32.50% to CNY 0.27[5] - Total revenue for the first three quarters of 2021 reached ¥3,213,201,476.59, an increase from ¥3,146,413,574.55 in the same period of 2020, representing a growth of approximately 2.1%[22] - Net profit for the third quarter of 2021 was ¥521,648,888.67, down from ¥637,566,383.83 in the same quarter of 2020, reflecting a decrease of approximately 18.2%[24] - The total comprehensive income attributable to the parent company for Q3 2021 was CNY 521,083,615.73, compared to CNY 637,255,433.23 in Q3 2020, representing a decrease of approximately 18.3%[26] - The basic and diluted earnings per share for Q3 2021 were both CNY 1.06, down from CNY 1.34 in Q3 2020, indicating a decline of about 20.9%[26] Assets and Liabilities - Total assets increased by 39.98% to CNY 7,710,988,911.71 compared to the end of the previous year[6] - Total current assets as of September 30, 2021, reached RMB 4,892,042,697.18, an increase from RMB 2,871,167,094.62 in the previous year[17] - The company’s total non-current assets were valued at RMB 2,835,000,000.00 as of September 30, 2021, compared to RMB 2,700,000,000.00 at the end of 2020[17] - The company’s total liabilities as of September 30, 2021, were RMB 3,500,000,000.00, reflecting a stable financial position[17] - The total liabilities decreased to ¥1,270,464,118.84 in Q3 2021 from ¥2,234,426,905.61 in Q3 2020, a reduction of approximately 43.2%[21] - The equity attributable to shareholders rose by 96.67% to CNY 6,440,544,494.22 compared to the end of the previous year[6] - The equity attributable to shareholders increased to ¥6,440,544,494.22 in Q3 2021 from ¥3,274,732,831.94 in Q3 2020, representing an increase of about 96.5%[21] Cash Flow - Cash flow from operating activities showed a significant decline of 107.44% year-to-date, resulting in a net outflow of CNY -50,481,356.46[5][8] - Cash inflow from operating activities for the first nine months of 2021 was CNY 1,799,024,987.26, compared to CNY 1,722,182,333.11 in the same period of 2020, reflecting an increase of approximately 4.5%[28] - The net cash flow from operating activities for the first nine months of 2021 was negative CNY 50,481,356.46, contrasting with a positive CNY 678,440,784.53 in the same period of 2020[28] - Cash inflow from investment activities for the first nine months of 2021 was CNY 1,196,583,611.02, significantly higher than CNY 507,948,250.33 in the same period of 2020, marking an increase of approximately 135.5%[29] - The net cash flow from investment activities for the first nine months of 2021 was negative CNY 1,467,101,349.96, compared to negative CNY 260,252,373.92 in the same period of 2020[29] - Cash inflow from financing activities for the first nine months of 2021 was CNY 2,938,582,578.68, compared to CNY 414,652,518.90 in the same period of 2020, indicating a substantial increase[29] - The net cash flow from financing activities for the first nine months of 2021 was CNY 1,930,678,325.30, contrasting with a negative CNY 254,082,367.15 in the same period of 2020[29] - The ending cash and cash equivalents balance as of the end of Q3 2021 was CNY 1,288,226,413.62, up from CNY 949,014,136.59 at the end of Q3 2020, representing an increase of approximately 35.7%[29] Shareholder Information - The company announced an automatic extension of the lock-up period for major shareholders by 6 months due to stock price conditions[14] - The company’s major shareholders include New Chang Ande Trading Co., Ltd., holding 23.08% of shares, and New Chang Qingyu Investment Development Co., Ltd., holding 13.12%[12] Operational Costs and Expenses - Total operating costs for the first three quarters of 2021 were ¥2,605,167,043.75, compared to ¥2,396,549,043.76 in 2020, indicating an increase of about 8.7%[22] - Research and development expenses for the first three quarters of 2021 were ¥106,211,901.82, compared to ¥96,927,165.16 in 2020, showing an increase of approximately 9.2%[22] - Financial expenses decreased significantly to ¥20,810,750.92 in Q3 2021 from ¥49,949,183.20 in Q3 2020, a reduction of about 58.3%[24] - The company reported a decrease in short-term borrowings to ¥235,242,905.56 in Q3 2021 from ¥509,407,335.28 in Q3 2020, a decline of approximately 53.8%[20] Return on Equity - The weighted average return on equity decreased by 3.73 percentage points to 2.61%[5] - The total liabilities to equity ratio improved significantly, indicating a stronger financial position for the company in Q3 2021 compared to Q3 2020[21]